Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses strategies for developing semi-solid topical generic products to match the quality of reference-listed drugs, using concepts like quality by design and reverse-engineering, but reports no new results.

This article describes the Australian Medicines Handbook as a compact, readable, and comprehensive drug reference guide for Australian practitioners, but it does not present new research findings.

This study found that monotherapy and topical medications are primarily used to treat pediatric skin diseases, with a variety of drugs prescribed indicating the complexity of these conditions.

This study highlighted the critical role emollients play in managing dry skin conditions and reported that prescribing suitable emollient therapy may reduce overall healthcare costs and the need for additional medications in UK primary care.

The document says that there are treatments for hair and nail diseases.

This study found that while 5α-reductase inhibitors like finasteride had many serious, unresolved adverse drug reactions, some were not listed in the existing product information.

This study found that tetracycline can adhere to hair follicle structures and disrupt cell metabolism, potentially damaging healthy human cells as well as pathogens.

This study found that a single application of 'Lye' or 'No-Lye' chemical straighteners significantly reduced drug concentrations in hair samples from both drug-fortified standards and authentic drug users.

This review discusses various therapeutic strategies targeting platelet-derived growth factor signaling in diseases like cancer and atherosclerosis, and evaluates existing treatments without presenting new clinical data.

Natural products might help treat hair greying.

Up to 50% of scalp hair can be lost before it appears thin, and treatment is only needed for hair loss caused by diseases or deficiencies.

This review discusses the role of skin manifestations as early markers and prognostic indicators of HIV infection in children but reports no new clinical results.

Adding a cosmetic gel with caffeine, taurine, and growth factors to standard hair loss treatments could improve results.

This article proposes naming the visual identification of androgenic alopecia in COVID-19 patients as the "Gabrin sign" to indicate higher risk for severe symptoms, but reports no new clinical results.

This review discusses various drugs and chemicals potentially causing hair loss, mechanisms involved, and suggests models for testing but reports no new clinical findings.

This study aimed to enhance the skin penetration of minoxidil by encapsulating it in glycerosomal vesicles, offering a potential improvement in transdermal drug delivery for treating androgenetic alopecia. Results of the investigation were not reported.

This review article examines current drugs for androgenetic alopecia, focusing on their mechanisms and clinical efficacy, noting that while finasteride and minoxidil are commonly approved treatments, new drugs targeting different pathogenic pathways have emerged, offering a broader understanding and reference for AGA treatment options.

This study found that paracellular transport significantly contributes to the intestinal permeability of minoxidil, suggesting its limited suitability as a Biopharmaceutics Classification System reference drug due to potential variability.

In this observational study of 110 women with PCOS, the researchers found that 52.7% experienced depression and anxiety, with Metformin being the most prescribed drug. Regular counseling and lifestyle management were noted to improve the overall disease prognosis.

This study suggests that while hair analysis using GC-MS is a sensitive method for detecting cocaine ingestion, it may not reliably indicate the amount, timing, or duration of drug use due to interindividual variability and multiple incorporation mechanisms.

This review concluded that WS PRO 160 I 120 mg, a herbal preparation, may be an effective and safer alternative to standard drugs for treating lower urinary tract symptoms in men with benign prostatic hyperplasia.

The study found that daily use of bimatoprost ophthalmic solution 0.03% for one year was effective in improving eyelash growth and patient satisfaction in both idiopathic and chemotherapy-induced hypotrichosis, with no serious drug-related adverse events reported.

This retrospective pharmacovigilance study reviewed adverse event reports from 2004 to 2025 for drugs treating benign prostatic hyperplasia, identifying distinct safety signals for α1-blockers, 5ARIs, and PDE5I, including some potential new adverse events that require further investigation.

This review assesses existing knowledge about the 17q21.31 inversion polymorphism, highlighting its genetic structure differences across ancestries, associations with various diseases, and implications for precision medicine and drug discovery.

Combination therapy of doxazosin and finasteride safely and effectively reduces benign prostatic hyperplasia progression risk.

This study found that finasteride effectively reduced hirsutism in women during 12 months of treatment, with some effects persisting in the majority after stopping the medication.

The book is a comprehensive and current guide on hair disorders, with minor flaws.

In this study, researchers analyzed adverse event reports from the FAERS database to identify safety concerns associated with ipilimumab in elderly patients, noting common issues like gastrointestinal events and new signals such as orchitis and alopecia areata, with timing influenced by body weight.

This article discusses a serious side effect associated with a potentially widely used cosmetic product but reports no new experimental results.

The document suggests that hair loss after stopping birth control may be similar to post-pregnancy hair loss and could recur with future pregnancies.